Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Qiufei Ma, Xue Song, Thomas E. Delea, Glenn S. Kroog, Wenzhen Ge, Lei Chi, Aaron Moynahan, Derek Weycker, Karen Rodriguez Lorenc

Blood (2022) 140 (Supplement 1): 5298–5300.

https://doi.org/10.1182/blood-2022-158142

Published: 2022

Journal Articles

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Wenzhen Ge, Alexi Archambault, Thomas E. Delea, Karen Rodriguez Lorenc, James Harnett, Aaron Moynahan, Derek Weycker, Yariv Houvras, Glenn S. Kroog, Ning Wu, Christian Hampp, Qiufei Ma

Blood (2022) 140 (Supplement 1): 10897–10899.

https://doi.org/10.1182/blood-2022-158013

Published: 2022

Journal Articles

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Nirmish Shah, Thokozeni Lipato, Thomas E. Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Ofelia A. Alvarez

Blood (2022) 140 (Supplement 1): 1954–1956.

https://doi.org/10.1182/blood-2022-169536

Published: 2022

Journal Articles

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Nirmish Shah, Thokozeni Lipato, Ofelia A. Alvarez, Thomas Delea, Alexander Lonshteyn, Derek Weycker, Andy Nguyen, Anne Beaubrun, Irene Agodoa

Blood (2021) 138 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2021-153138

Published: 2021

Journal Articles

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Ahmar Urooj Zaidi, MD, Thokozeni Lipato, MD, Ofelia A. Alvarez, MD, Alexander Lonshteyn, PhD, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140525

Published: 2020

Journal Articles

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

William B Ershler, MD, Laura M De Castro, MD MHSc, Zahra Pakbaz, MD, Aaron Moynahan, Derek Weycker, PhD, Nhat Pham, Thomas E Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140572

Published: 2020

Journal Articles

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Gary H. Lyman, MD MPH, Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 5854.

https://doi.org/10.1182/blood-2019-123524

Published: 2019

Journal Articles

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Gary H. Lyman, MD MPH, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 4688.

https://doi.org/10.1182/blood-2019-123559

Published: 2019

Journal Articles

Effectiveness of Romiplostim for Treatment of Adults with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia in US Clinical Practice

Mark Hatfield, PhD, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Ahuva Hanau, BS, Alex Lonshteyn, PhD, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 4668.

https://doi.org/10.1182/blood-2019-123999

Published: 2019

Journal Articles

Immune Thrombocytopenia in US Clinical Practice: Incidence and Healthcare Utilization/Expenditures in the First 12 Months Following Diagnosis

Derek Weycker, PhD, Aaron Grossman, MD MPH, Ahuva Hanau, BS, Hongsheng Wu, PhD, Mark Hatfield, PhD, Anjali Sharma, MD, Mark E. Bensink, PhD MSc, MD, David Chandler, PhD, Michael D. Tarantino, MD

Blood (2018) 132 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2018-99-113429

Published: 2018

Journal Articles

Use and Patterns of Supportive Care Among Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Colorectal Cancer, Lung Cancer, or Non-Hodgkin's Lymphoma in US Clinical Practice

Derek Weycker, PhD, Amanda Silvia, BS, Kathryn Richert-Boe, MD MPH, Mark Bensink, PhD MS, James O. Brady, MD, Lois Lamerato, PhD, Heather Lipkovich, MPH, Ahmad Daniyal Siddiqui, MD, David Chandler, PhD MBA

Blood (2016) 128 (22): 5909.

https://doi.org/10.1182/blood.V128.22.5909.5909

Published: 2016

Journal Articles

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Derek Weycker, PhD, Xiaoyan Li, PhD, Rich Barron, M.S., Hongsheng Wu, PhD, Phuong Khanh Morrow, MD, Hairong Xu, MD, PhD, Maureen Reiner, M.S., Jacob Garcia, MD, Shivani Mhatre, M.S., Gary H. Lyman, MD MPH

Blood (2014) 124 (21): 4824.

https://doi.org/10.1182/blood.V124.21.4824.4824

Published: 2014

Journal Articles

Use of Chemotherapy and Same-Day Pegfilgrastim Prophylaxis in US Clinical Practice

Derek Weycker, PhD, Hongsheng Wu, PhD, May Hagiwara, PhD, Xiaoyan Li, PhD, Richard L Barron, MS

Blood (2014) 124 (21): 4825.

https://doi.org/10.1182/blood.V124.21.4825.4825

Published: 2014

Journal Articles

Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice

Derek Weycker, Ph.D., David Chandler, Ph.D., Rich Barron, M.S., Hairong Xu, M.D., Ph.D., Hongsheng Wu, Ph.D., Vincent Girardi, M.S., John Edelsberg, M.D., M.P.H., Gary H. Lyman, M.D., M.P.H.

Blood (2013) 122 (21): 1730.

https://doi.org/10.1182/blood.V122.21.1730.1730

Published: 2013

Journal Articles

Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy

Derek Weycker, Ph.D., Xiaoyan Li, Ph.D., Alex Kartashov, Ph.D., Rich Barron, M.S., John Edelsberg, M.D., M.P.H., Hairong Xu, M.D., Ph.D., Vincent Girardi, M.S., Gary H. Lyman, M.D., M.P.H.

Blood (2013) 122 (21): 2962.

https://doi.org/10.1182/blood.V122.21.2962.2962

Published: 2013

Journal Articles

Incidence, Treatment, and Consequences of Chemotherapy-Induced Febrile Neutropenia in Inpatient and Outpatient Settings

Derek Weycker, Ph.D., Richard Barron, MS, Alex Kartashov, Ph.D., Jason C. Legg, Gary H. Lyman, MD, MPH

Blood (2012) 120 (21): 4232.

https://doi.org/10.1182/blood.V120.21.4232.4232

Published: 2012

Journal Articles

Cost of Chemotherapy-Induced Febrile Neutropenia Treated in Inpatient, Outpatient, and Home Settings Among Adults with Non-Hodgkin's Lymphoma in European Clinical Practice,

Derek Weycker, Ph.D., Aurelie Danel, Pharm.D., Kate Bendall, M.Sc., Michael Lipsitz, Ruth Pettengell, M.D.

Blood (2011) 118 (21): 4200.

https://doi.org/10.1182/blood.V118.21.4200.4200

Published: 2011

NARROW

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Effectiveness of Romiplostim for Treatment of Adults with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia in US Clinical Practice

Immune Thrombocytopenia in US Clinical Practice: Incidence and Healthcare Utilization/Expenditures in the First 12 Months Following Diagnosis

Use and Patterns of Supportive Care Among Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Colorectal Cancer, Lung Cancer, or Non-Hodgkin's Lymphoma in US Clinical Practice

Incidence of Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified As High-Risk in Guidelines for Myeloid Growth Factor Use: Importance of “Risk Factor Stacking”

Use of Chemotherapy and Same-Day Pegfilgrastim Prophylaxis in US Clinical Practice

Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice

Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy

Incidence, Treatment, and Consequences of Chemotherapy-Induced Febrile Neutropenia in Inpatient and Outpatient Settings

Cost of Chemotherapy-Induced Febrile Neutropenia Treated in Inpatient, Outpatient, and Home Settings Among Adults with Non-Hodgkin's Lymphoma in European Clinical Practice,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only